DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 216 filers reported holding DENALI THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,270,723 | -58.2% | 110,069 | -53.3% | 0.01% | -72.7% |
| Q1 2023 | $5,429,652 | +1224.3% | 235,662 | +1663.3% | 0.02% | +1000.0% |
| Q3 2022 | $410,000 | -63.0% | 13,365 | -61.2% | 0.00% | -60.0% |
| Q1 2022 | $1,108,000 | +27.6% | 34,435 | +100.2% | 0.01% | +150.0% |
| Q3 2021 | $868,000 | -39.7% | 17,200 | -6.3% | 0.00% | -60.0% |
| Q2 2021 | $1,439,000 | +373.4% | 18,350 | +244.4% | 0.01% | +150.0% |
| Q1 2021 | $304,000 | -41.1% | 5,328 | -63.0% | 0.00% | -71.4% |
| Q3 2020 | $516,000 | +80.4% | 14,411 | -22.8% | 0.01% | +133.3% |
| Q3 2019 | $286,000 | -55.5% | 18,657 | -39.7% | 0.00% | -50.0% |
| Q2 2019 | $642,000 | -73.7% | 30,936 | -70.6% | 0.01% | -76.9% |
| Q1 2019 | $2,441,000 | – | 105,140 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |